Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Urology

The Long Road: Life and Monitoring After Diagnosis

At a Glance

Long-term BPH care usually includes follow-up once or twice a year when symptoms are stable, symptom and bladder checks, PSA monitoring after treatment, and prompt review of worsening symptoms, retention, bleeding, or kidney strain.

Managing Benign Prostatic Hyperplasia (BPH) is often a marathon, not a sprint. Whether you are currently using “watchful waiting,” taking daily medication, or recovering from a procedure, long-term care focuses on protecting your bladder and kidney health while maintaining your quality of life [1].

Understanding what to expect in the years following diagnosis can help you partner with your doctor to catch any changes early.

Long-Term Monitoring and Surveillance

There is no “one-size-fits-all” schedule for BPH check-ups, but your care will likely follow a consistent pattern.

For Watchful Waiting or Medication

If your symptoms are stable, you will typically see your urologist or primary care doctor once or twice a year [2]. During these visits, the following tools may be used depending on your symptoms:

  • IPSS/AUA-SI Score: This is the most important way to track if your symptoms are worsening over time [1].
  • Post-Void Residual (PVR): Occasional ultrasounds ensure your bladder isn’t starting to “retain” too much urine, which can be a silent sign of progression [3].
  • Uroflowmetry: You may be asked to urinate into a special machine that measures the strength and speed of your stream [3].
  • Bladder Diaries: If you are still waking up frequently at night (nocturia), your doctor may ask you to record your fluid intake and bathroom trips for 48–72 hours [3].

Triggers for Changing Your Plan

“Watchful waiting” isn’t a permanent decision. You and your doctor should consider more active treatment if you experience:

  • Symptoms that no longer respond to medication or refractory symptoms [1].
  • Recurrent Urinary Tract Infections (UTIs) [1].
  • Visible blood in the urine, which requires a prompt hematuria workup [3].
  • Signs of kidney strain or “back-pressure” (hydronephrosis) [3].
  • Recurrent urinary retention.

The Reality of Retreatment

While many procedures provide relief for a decade or more, BPH is a condition driven by aging, and the prostate can sometimes continue to grow or cause new blockages. The “durability” of your treatment—how long it lasts before a second procedure is needed—depends heavily on which method you chose [4].

Research into 5-year retreatment rates shows a general trend:

  • Minimally Invasive (MISTs): Procedures like UroLift and Rezūm do not have interchangeable rates, but generally have higher retreatment rates than definitive surgeries, ranging from 11% to 16% at five years [4][5].
  • Definitive Surgeries: TURP has a lower retreatment rate (around 7%), while HoLEP is among the most durable, with retreatment rates often below 5% [4][6].
  • Aquablation: Early data suggests a 5-year retreatment risk of approximately 4.4% to 6% [5].

Why Some Symptoms Persist After Surgery

It is common for men to be surprised when “urgency” or “frequency” continues even after a successful surgery has cleared the blockage. This happens because the prostate was only one part of the problem—the bladder has also changed [7].

Years of pushing against an obstructed prostate can cause the bladder wall to become thick and irritable, a process called remodeling [7]. This can lead to persistent Overactive Bladder (OAB) symptoms [8]. In many cases, these symptoms improve over 3 to 6 months as the bladder “heals” and regains its normal blood flow [9]. If they persist longer, your doctor may add bladder-specific medications like mirabegron to help the bladder relax [10].

Monitoring PSA After Treatment

Your Prostate-Specific Antigen (PSA) levels will change significantly depending on your treatment, which creates a “new normal” for your cancer screening:

  • After 5-ARIs (Finasteride/Dutasteride): These drugs roughly cut your PSA level in half, though this is not an automatic “normalization” rule. If your PSA was 4.0 before treatment, a “normal” reading while on the drug might be 2.0, but your doctor will interpret this [11].
  • After HoLEP or TURP: These surgeries remove a large amount of prostate tissue, causing the PSA to drop drastically. However, the drop depends on the amount of tissue removed and remaining, so it is not universally 90% or below 1.0 [12].
  • The “New Baseline”: It is essential to establish a new “baseline” PSA about 3 to 6 months after any procedure [13]. Any significant rise from this new low point, even if the number still seems “small,” should be discussed with your urologist [14].

By staying consistent with your follow-up appointments, you can ensure that BPH remains a manageable part of your life rather than a source of constant worry. If you experience fever, heavy bleeding, or sudden inability to urinate during recovery, contact your doctor immediately.

Common questions in this guide

How often should I have follow-up visits for BPH?
There is no single schedule, but people with stable symptoms often see a urologist or primary care clinician once or twice a year. Visits may include a symptom score, a check for urine left in the bladder after urinating, a urine-flow test, or a bladder diary depending on your symptoms.
What symptoms mean my BPH treatment may need to change?
Symptoms that do not improve with medication, repeated urinary tract infections, visible blood in the urine, repeated inability to urinate, or signs of pressure affecting the kidneys should be reviewed promptly. These findings may lead you and your clinician to consider a procedure or another active treatment.
Why do urgency and frequent urination continue after BPH surgery?
Long-standing blockage can change the bladder wall, making it overactive even after the prostate blockage is relieved. Urgency and frequent urination often improve over three to six months, but a clinician may consider a bladder-specific medicine such as mirabegron if they persist.
How does BPH treatment affect my PSA level?
Finasteride and dutasteride usually lower PSA by about half, so the result must be interpreted in light of the medicine. HoLEP and TURP can lower PSA substantially by removing prostate tissue; after a procedure, clinicians commonly establish a new PSA baseline around three to six months later and investigate a significant rise.
How likely am I to need another BPH procedure?
The risk depends on the treatment and your individual situation. At five years, retreatment is reported at about 11% to 16% for some minimally invasive treatments such as UroLift and Rezūm, around 7% after TURP, often below 5% after HoLEP, and about 4.4% to 6% after Aquablation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current treatment, how often should we be repeating my IPSS symptom score and PVR ultrasound?
  2. 2.If my urgency symptoms haven't improved six months after my procedure, should we consider adding a bladder-specific medication or doing a 'pressure-flow' study?
  3. 3.Since I am taking a 5-alpha reductase inhibitor (like finasteride), what is my 'corrected' PSA level for cancer screening purposes?
  4. 4.What is the new PSA 'baseline' or 'nadir' I should expect after my HoLEP or TURP procedure, and at what point would a rising PSA become a concern?
  5. 5.Given the procedure I had, what is the statistical likelihood I will need a second operation within the next five to ten years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

    Smetana GW, Smith CC, Singla A, Libman H

    Annals of internal medicine 2023; (176(4)):545-555 doi:10.7326/M23-0113.

    PMID: 37037036
  2. 2

    Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study.

    Yamazaki H, Tsujimoto N, Koyanagi M, et al.

    Pragmatic and observational research 2020; (11()):45-54 doi:10.2147/POR.S237821.

    PMID: 32440247
  3. 3

    EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

    Gratzke C, Bachmann A, Descazeaud A, et al.

    European urology 2015; (67(6)):1099-1109 doi:10.1016/j.eururo.2014.12.038.

    PMID: 25613154
  4. 4

    Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos.

    Carletti F, Tamborino F, Turcan A, et al.

    European urology focus 2026; (12(3)):383-392 doi:10.1016/j.euf.2026.01.003.

    PMID: 41558957
  5. 5

    Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.

    Akgul B, Tozsin A, Aydın A, et al.

    World journal of urology 2025; (43(1)):494 doi:10.1007/s00345-025-05884-y.

    PMID: 40817983
  6. 6

    Impact of Endoscopic Bladder Outlet Procedures on Medical and Surgical Retreatment: A Large Population Analysis.

    Helman T, Patil D, Marthi S, Browne B

    Journal of endourology 2025; (39(6)):608-616 doi:10.1089/end.2024.0741.

    PMID: 40227061
  7. 7

    Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI-RS 2023.

    Tarcan T, Hashim H, Malde S, et al.

    Neurourology and urodynamics 2024; (43(6)):1447-1457 doi:10.1002/nau.25435.

    PMID: 38477358
  8. 8

    Is there concordance between overactive bladder and detrusor overactivity in men with predominant storage urinary symptoms referred to Functional Urology and Urodynamics Units?

    Esteban-Fuertes M, Prieto-Chaparro L, Arlandis-Guzmán S, et al.

    Actas urologicas espanolas 2021; doi:10.1016/j.acuro.2021.06.002.

    PMID: 34332808
  9. 9

    The Impact of Increased Bladder Blood Flow on Storage Symptoms after Holmium Laser Enucleation of the Prostate.

    Saito K, Hisasue S, Ide H, et al.

    PloS one 2015; (10(6)):e0129111 doi:10.1371/journal.pone.0129111.

    PMID: 26090819
  10. 10

    Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.

    Sebastianelli A, Russo GI, Kaplan SA, et al.

    International journal of urology : official journal of the Japanese Urological Association 2018; (25(3)):196-205 doi:10.1111/iju.13498.

    PMID: 29205506
  11. 11

    Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study.

    Obinata D, Suzuki S, Yamanaka Y, et al.

    Andrologia 2020; (52(11)):e13810 doi:10.1111/and.13810.

    PMID: 32816374
  12. 12

    Impact of perioperative factors on nadir serum prostate-specific antigen levels after holmium laser enucleation of prostate.

    Martos M, Katz JE, Parmar M, et al.

    BJUI compass 2021; (2(3)):202-210 doi:10.1002/bco2.68.

    PMID: 35475131
  13. 13

    Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.

    Bhat A, Blachman-Braun R, Herrmann TRW, Shah HN

    World journal of urology 2022; (40(4)):889-905 doi:10.1007/s00345-021-03771-w.

    PMID: 34212237
  14. 14

    Changes in serum PSA after endoscopic enucleation of the prostate are predictive for the future diagnosis of prostate cancer.

    Lambert E, Goossens M, Palagonia E, et al.

    World journal of urology 2021; (39(7)):2621-2626 doi:10.1007/s00345-020-03444-0.

    PMID: 32997261

This page is for informational purposes only and does not constitute medical advice. Your urologist or primary care clinician should tailor BPH follow-up, PSA interpretation, and treatment decisions to your situation.

Get notified when new evidence is published on benign prostatic hyperplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.